Main Article Content
Objective: To study the effect of Telbuvidine (LDT) monotherapy in the treatment of HBeAg positiveChronic Hepatitis B infection (CHB) with normal ALT levels.
Methodology: Ninety HBe antigen (HBeAg) positive CHB infection patients were enrolled & followedbetween June 2008 and June 2011. All of them had ALT levels less than twice the upper normal limit(Mean 36.9 SD 19.9). All patients were HBeAg positive, had serum DNA level Ëƒ104 copies/ml and neverhad previously received anti HBV treatment. All patients were given LDT 600mg daily as initial antiviraltreatment for two years.
Results: Out of 83 patients who continued the treatment as per protocol, 59 were males and 24 werefemales between ages of 21 and 50 years. Baseline HBV DNA levels were 7.82x107 copies/ml (Range4.8x104-8.3x109copies/ml). By the end of first year (52 weeks) the mean decrease in serum HBV DNA levelswas 7.88 log10 copies/ml and the proportion of patients having undetectable HBV DNA levels was 73%. Atthe end of second year of therapy (96 weeks) the percentage of undetectable HBV DNA levels increased to86%.At the end of 1st (52weeks) and 2nd (96weeks) HBeAg seroconversion rates were 62 % and 86% whileHBsAg seroconversion was 8% and 13% respectively.
Conclusion: LDT is a reasonable cost effective therapy for HBeAg reactive CHB patients with normalbaseline ALT levels resulting in a significant serological and virological response and was well toleratedin our population of Khyber Pukhtunkhwa.
Work published in JPMI is licensed under a
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.